A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]

Randi Hagerman,1 Elizabeth Berry-Kravis,2 Dejan Budimirovic,3 Craig Erickson,4 Helen Heussler,5 Nicole Tartaglia,6 Jonathan Cohen,7 Thomas Dobbins,8 Elizabeth Merikle,9 Terri Sebree,10 Nancy Tich,10 Joseph M. Palumbo10

1University of California Davis Medical Center, Department of Pediatrics and MIND Institute, Sacramento, CA, USA; 2Rush University Medical Center, Chicago, IL, USA; 3Departments of Psychiatry and Neurogenetics, Fragile X Clinic, Kennedy Krieger Institute, Baltimore, MD, USA; 4Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 5Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children’s Health Queensland, QLD, AU; 6Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA; 7Fragile X Alliance, North Caulfield, VIC, Australia; 8The Griesser Group, Conshohocken, PA, USA; 9Lapcorp Drug Development, Gaithersburg, MD, USA; 10Zynerba Pharmaceuticals, Devon, PA, USA

Disclosures: TS, N Tich, and JP are employees of Zynerba Pharmaceuticals. TD is a contractor for Zynerba Pharmaceuticals. RH, EBK, CDB, E, RH, N Tartaglia, CE, HH, and JC have received research support from Zynerba Pharmaceuticals. The study was funded by Zynerba Pharmaceuticals.
Disclaimers

• This presentation is intended to communicate scientific and medical information about data from clinical trials involving ZYN002. ZYN002 is an experimental treatment which has not been approved by any government regulatory bodies, including the United States Food and Drug Administration (FDA), and has not been determined by the FDA to be a safe or effective treatment for any disease or condition. This presentation is not designed or intended to promote the use of ZYN002 or any other Company product in order to impact prescribing.

• This slide presentation is based on an abstract submitted and accepted for presentation at the 2021 Society of Developmental & Behavioral Pediatrics Annual Meeting.
CONNECT-FX: Clinical study Of CaNNabidiol (CBD) in ChildrEn and AdolesCenTs with Fragile X

CONNECT-FX is a randomized, double-blind, multinational, 14-week pivotal study to evaluate the efficacy and safety of ZYN002 in children/adolescents aged 3 through 17 years with a full FMR1 gene mutation.

- ZYN002 did not statistically significantly separate from placebo on the primary or key secondary endpoints in the full analysis set.
- Building on current scientific evidence, a pre-planned ad hoc analysis of patients having at least 90% methylation of the impacted FMR1 gene was performed.
  - The results suggest that ZYN002 may have benefit in patients with ≥90% methylation of the FMR1 gene.

\(^a\)FMR1 methylation status was determined by using Southern blot analysis.
In Patients With ≥90% Methylation of FMR1, Statistical Significance Was Achieved on Social Avoidance at Week 12 (ABC-CFXS)

- Mean (years): 9.6 (placebo), 9.2 (ZYN002)
- Male sex: 70% (placebo), 71% (ZYN002)

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>Placebo N=76</th>
<th>ZYN002 N=91</th>
<th>Treatment Difference / Odds Ratio†</th>
<th>Treatment p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Endpoint</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social Avoidance</td>
<td>Baseline Mean (SE)</td>
<td>Week 12 Mean (SE)</td>
<td>Week 12 Median Percent Change</td>
<td>Baseline Mean (SE)</td>
</tr>
<tr>
<td></td>
<td>7.18 (0.32)</td>
<td>5.41 (0.42)</td>
<td>-21.1</td>
<td>7.12 (0.29)</td>
</tr>
<tr>
<td>Irritability</td>
<td>28.0 (1.56)</td>
<td>24.11 (1.56)</td>
<td>-11.6</td>
<td>29.36 (1.37)</td>
</tr>
<tr>
<td>Socially Unresponsive/ Lethargic</td>
<td>13.17 (0.85)</td>
<td>10.29 (0.80)</td>
<td>-20.5</td>
<td>13.30 (0.68)</td>
</tr>
<tr>
<td>CGI-I</td>
<td>-</td>
<td>35.7%</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Trend level response achieved in Irritability and CGI-I
CGI-I defined as “any improvement”

*Statistically significant.
Data on file.
Meaningful Change in ABC-CFXS Social Avoidance and Irritability and Caregiver Global Impression of Change With ZYN002 vs Placebo

**ABC-CFXS Social Avoidance and Irritability**

- **Social Avoidance (Change ≥ 3)**
  - Placebo: 40.6%
  - ZYN002: 58.2%
  - OR: 2.17, P=0.031*

- **Irritability (Change ≥ 9)**
  - Placebo: 40.3%
  - ZYN002: 31.7%
  - OR: 1.57, P=0.184

- **Socially Unresponsive/ Lethargic (Change ≥ 5)**
  - Placebo: 42.1%
  - ZYN002: 40.0%

*Statistically significant. LS Means

**Caregiver Global Impression of Change**

- **Social Avoidance and Isolation**
  - Placebo: 31.7%
  - ZYN002: 42.1%
  - OR: 1.57, P=0.038*

- **Irritable and Disruptive Behaviors**
  - Placebo: 30.7%
  - ZYN002: 40.3%
  - OR: 2.04, P=0.031*

- **Social Interactions**
  - Placebo: 31.7%
  - ZYN002: 42.1%
  - OR: 1.57, P=0.038*

- **Overall Behavior**
  - Placebo: 31.7%
  - ZYN002: 42.1%

OR= odds ratio

Data on File.
Post-hoc analysis in the 100% Methylation Population Representing 65% of Patients

Significant treatment effect also demonstrated in the smaller, complete methylation population, further supporting importance of methylation of *FMR1* gene

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>ZYN002 N = 72</th>
<th>Placebo** N = 64</th>
<th>Treatment Difference / Odds Ratio</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC-C&lt;sub&gt;FXS&lt;/sub&gt; Social Avoidance Mean change</td>
<td>- 2.92</td>
<td>- 1.84</td>
<td>- 1.08</td>
<td>0.027*</td>
</tr>
<tr>
<td>% change (median)</td>
<td>- 40%</td>
<td>- 20%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meaningful Change (≥ 3 points)</td>
<td>56%</td>
<td>37%</td>
<td>2.25</td>
<td>0.03*</td>
</tr>
<tr>
<td>Social avoidance / isolation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caregiver global impression-Change (≥ 1 point)</td>
<td>63%</td>
<td>37%</td>
<td>2.91</td>
<td>0.005*</td>
</tr>
<tr>
<td>Social interactions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caregiver global impression-Change (≥ 1 point)</td>
<td>54%</td>
<td>33%</td>
<td>2.36</td>
<td>0.027*</td>
</tr>
<tr>
<td>Irritable / disruptive behaviors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Statistically significant

**Placebo N = 65, however, one patient did not have a post-baseline efficacy measure and was therefore not included in the efficacy analysis
CONNECT-FX Safety

Safety

• ZYN002 was very well tolerated in CONNECT-FX

• There were no serious or severe adverse events reported during the study

• All treatment-emergent adverse events (TEAEs) (any event, whether unrelated or related to study drug) were mild or moderate
  • The most common treatment-related TEAE was application site pain (ZYN002: 6.4%; placebo: 1.0%)

• Laboratory values for chemistry and hematology were comparable between the placebo and ZYN002 treatment groups, and there were no clinically relevant abnormalities in either group
  • There were no clinically significant changes to liver function tests
CONNECT-FX: ZYN002 in Fragile X Syndrome

Summary

• ZYN002 was well tolerated

• In the ≥90% and 100% methylation groups, ZYN002 was superior to placebo in multiple analyses

• The data suggest that effective silencing of the *FMR1* gene may have led to differences in treatment response in patients with ≥90% methylation of the *FMR1* gene

• These results may represent an important step forward in further understanding FXS and the importance of methylation of the *FMR1* gene

• A follow-up Phase 3 study, RECONNECT [ZYN2-CL-033], is being conducted to confirm these results in patients with complete (100%) and partial methylation (<100%)